TY - JOUR
T1 - Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein
AU - Thorburn, Jacqueline
AU - Frankel, Arthur E.
AU - Thorburn, Andrew
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Purpose: We examined the mechanism of action of a targeted fusion toxin consisting of diphtheria toxin fused to granulocyte macrophage colony stimulating factor (GMCSF) (DT388-GMCSF), which was designed to selectively kill acute myeloid leukemia cells. Experimental design and Results: U937 cells treated with DT388-GMCSF underwent apoptosis as shown by chromatin degradation and cellular and nuclear fragmentation. This apoptosis was prevented by a general caspase inhibitor. DT388-GMCSF treatment resulted in activation of the initiator caspases 8 and 9 and effector caspases. A selective caspase 8 inhibitor prevented activation of caspase 9, whereas a selective caspase 9 inhibitor did not prevent activation of caspase 8, indicating that caspase 8 activation is the proximal event in DT388-GMCSF-induced apoptosis. Caspase 8 was activated through a Fas-associated death domain protein (FADD)-dependent mechanism as demonstrated by inhibition of DT388-GMCSF-induced apoptosis on expression of a dominant negative FADD molecule. However, unlike most FADD-dependent apoptosis, this pathway may not involve death receptors, including Fas, tumor necrosis factor receptor 1, or tumor necrosis factor-related apoptosis-inducing ligand receptors, because inhibitors of the receptors did not prevent DT388-GMCSF-induced apoptosis. Conclusions: These data indicate that targeted toxins induce apoptosis by activating components of the death receptor pathway in a receptor-independent manner.
AB - Purpose: We examined the mechanism of action of a targeted fusion toxin consisting of diphtheria toxin fused to granulocyte macrophage colony stimulating factor (GMCSF) (DT388-GMCSF), which was designed to selectively kill acute myeloid leukemia cells. Experimental design and Results: U937 cells treated with DT388-GMCSF underwent apoptosis as shown by chromatin degradation and cellular and nuclear fragmentation. This apoptosis was prevented by a general caspase inhibitor. DT388-GMCSF treatment resulted in activation of the initiator caspases 8 and 9 and effector caspases. A selective caspase 8 inhibitor prevented activation of caspase 9, whereas a selective caspase 9 inhibitor did not prevent activation of caspase 8, indicating that caspase 8 activation is the proximal event in DT388-GMCSF-induced apoptosis. Caspase 8 was activated through a Fas-associated death domain protein (FADD)-dependent mechanism as demonstrated by inhibition of DT388-GMCSF-induced apoptosis on expression of a dominant negative FADD molecule. However, unlike most FADD-dependent apoptosis, this pathway may not involve death receptors, including Fas, tumor necrosis factor receptor 1, or tumor necrosis factor-related apoptosis-inducing ligand receptors, because inhibitors of the receptors did not prevent DT388-GMCSF-induced apoptosis. Conclusions: These data indicate that targeted toxins induce apoptosis by activating components of the death receptor pathway in a receptor-independent manner.
UR - http://www.scopus.com/inward/record.url?scp=0037312490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037312490&partnerID=8YFLogxK
M3 - Article
C2 - 12576460
AN - SCOPUS:0037312490
SN - 1078-0432
VL - 9
SP - 861
EP - 865
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -